Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TK1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
GO:190129313 | Breast | IDC | nucleoside phosphate biosynthetic process | 41/1434 | 256/18723 | 5.15e-06 | 1.73e-04 | 41 |
GO:00718976 | Breast | IDC | DNA biosynthetic process | 26/1434 | 180/18723 | 1.28e-03 | 1.35e-02 | 26 |
GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
GO:19907489 | Cervix | CC | cellular detoxification | 30/2311 | 116/18723 | 5.34e-05 | 7.94e-04 | 30 |
GO:00972379 | Cervix | CC | cellular response to toxic substance | 31/2311 | 124/18723 | 8.09e-05 | 1.10e-03 | 31 |
GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
GO:00987549 | Cervix | CC | detoxification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
GO:000963624 | Cervix | N_HPV | response to toxic substance | 27/534 | 262/18723 | 9.00e-09 | 1.71e-06 | 27 |
GO:009886924 | Cervix | N_HPV | cellular oxidant detoxification | 13/534 | 101/18723 | 5.89e-06 | 2.15e-04 | 13 |
GO:009723724 | Cervix | N_HPV | cellular response to toxic substance | 14/534 | 124/18723 | 1.22e-05 | 4.06e-04 | 14 |
GO:199074824 | Cervix | N_HPV | cellular detoxification | 13/534 | 116/18723 | 2.69e-05 | 7.30e-04 | 13 |
GO:009875424 | Cervix | N_HPV | detoxification | 15/534 | 152/18723 | 3.05e-05 | 8.02e-04 | 15 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0098754 | Colorectum | AD | detoxification | 53/3918 | 152/18723 | 4.63e-05 | 7.98e-04 | 53 |
GO:1901293 | Colorectum | AD | nucleoside phosphate biosynthetic process | 80/3918 | 256/18723 | 6.31e-05 | 1.05e-03 | 80 |
GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
GO:0097237 | Colorectum | AD | cellular response to toxic substance | 44/3918 | 124/18723 | 1.24e-04 | 1.80e-03 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TK1 | SNV | Missense_Mutation | rs373525383 | c.197G>A | p.Cys66Tyr | p.C66Y | P04183 | protein_coding | tolerated(0.66) | benign(0) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TK1 | insertion | Nonsense_Mutation | novel | c.124_125insATTTGAACATTGAATGATTCAAATCAGCACACTTTCCAAGG | p.Arg42HisfsTer6 | p.R42Hfs*6 | P04183 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TK1 | insertion | Nonsense_Mutation | novel | c.177_178insTGGTTTGGCCTGCACGTTGATTTTTGTTTAATTTTTTAGTTGTC | p.Arg60TrpfsTer13 | p.R60Wfs*13 | P04183 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
TK1 | SNV | Missense_Mutation | | c.697N>A | p.Ala233Thr | p.A233T | P04183 | protein_coding | tolerated_low_confidence(0.05) | benign(0.001) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TK1 | SNV | Missense_Mutation | novel | c.536N>G | p.Asp179Gly | p.D179G | P04183 | protein_coding | deleterious(0.01) | benign(0.228) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
TK1 | SNV | Missense_Mutation | rs375708499 | c.245G>A | p.Arg82Gln | p.R82Q | P04183 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-CM-5349-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TK1 | SNV | Missense_Mutation | | c.527N>T | p.Gly176Val | p.G176V | P04183 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
TK1 | SNV | Missense_Mutation | rs746414831 | c.224N>T | p.Ala75Val | p.A75V | P04183 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TK1 | SNV | Missense_Mutation | novel | c.236N>A | p.Cys79Tyr | p.C79Y | P04183 | protein_coding | deleterious(0.04) | benign(0.08) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TK1 | SNV | Missense_Mutation | | c.612G>T | p.Glu204Asp | p.E204D | P04183 | protein_coding | tolerated(0.08) | benign(0.132) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | zidovudine | ZIDOVUDINE | 22960662 |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy | | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | Ad-OC-hsvTK/valacyclovir | | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | HQK-1004 | ARGININE BUTYRATE | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | Radiosensitizer gene therapy | | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | TK-DLI | | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | FV-100 | VALNIVUDINE HYDROCHLORIDE | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | Penciclovir | PENCICLOVIR | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | DEOXYCYTIDINE | DEOXYCYTIDINE | |
7083 | TK1 | ENZYME, KINASE, DRUGGABLE GENOME | | Rilapladib | RILAPLADIB | |